These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 25026210)

  • 1. Response to Chauhan et Al.: interstitial pressure and vascular collapse in pancreas cancer-fluids and solids, measurement and meaning.
    DelGiorno KE; Carlson MA; Osgood R; Provenzano PP; Brockenbough JS; Thompson CB; Shepard HM; Frost GI; Potter JD; Hingorani SR
    Cancer Cell; 2014 Jul; 26(1):16-7. PubMed ID: 25026210
    [No Abstract]   [Full Text] [Related]  

  • 2. Compression of pancreatic tumor blood vessels by hyaluronan is caused by solid stress and not interstitial fluid pressure.
    Chauhan VP; Boucher Y; Ferrone CR; Roberge S; Martin JD; Stylianopoulos T; Bardeesy N; DePinho RA; Padera TP; Munn LL; Jain RK
    Cancer Cell; 2014 Jul; 26(1):14-5. PubMed ID: 25026209
    [No Abstract]   [Full Text] [Related]  

  • 3. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
    Provenzano PP; Cuevas C; Chang AE; Goel VK; Von Hoff DD; Hingorani SR
    Cancer Cell; 2012 Mar; 21(3):418-29. PubMed ID: 22439937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete pathological response after chemotherapy alone in a patient with pancreatic adenocarcinoma.
    Carbonell S; Espinosa J; Zarco A; de-Madaria E; de la Hoz J; Yuste A; Payá A; Lluís F
    Pancreas; 2012 May; 41(4):657-9. PubMed ID: 22504386
    [No Abstract]   [Full Text] [Related]  

  • 5. [nab-Paclitaxel as new therapeutic option for pancreatic cancer].
    Michl P
    Z Gastroenterol; 2013 Nov; 51(11):1329-30. PubMed ID: 24243574
    [No Abstract]   [Full Text] [Related]  

  • 6. A New Scalpel for the Treatment of Pancreatic Cancer: Targeting Stromal-Derived STAT3 Signaling.
    Cowan RW; Maitra A; Rhim AD
    Gastroenterology; 2015 Dec; 149(7):1685-8. PubMed ID: 26526714
    [No Abstract]   [Full Text] [Related]  

  • 7. Chemotherapy: NAPOLI-1: winning scoop for metastatic pancreatic cancer.
    Hutchinson L
    Nat Rev Clin Oncol; 2016 Jan; 13(1):2-3. PubMed ID: 26667974
    [No Abstract]   [Full Text] [Related]  

  • 8. Nanoliposomal irinotecan in metastatic pancreatic cancer.
    Milosevic I; Drysdale H; Goldacre B;
    Lancet; 2016 May; 387(10032):1997. PubMed ID: 27203772
    [No Abstract]   [Full Text] [Related]  

  • 9. Gemcitabine-resistant pancreatic cancer: a second-line option.
    Oettle H; Lehmann T
    Lancet; 2016 Feb; 387(10018):507-508. PubMed ID: 26616909
    [No Abstract]   [Full Text] [Related]  

  • 10. Nanoliposomal irinotecan in metastatic pancreatic cancer - Authors' reply.
    Chen LT; Wang-Gillam A; Von Hoff DD; Bayever E; Belanger B
    Lancet; 2016 May; 387(10032):1997. PubMed ID: 27203770
    [No Abstract]   [Full Text] [Related]  

  • 11. Predicting a response to FOLFIRINOX in pancreatic cancer.
    Nipp RD; Ryan DP
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26025325
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvals.
    Bates SE; Fojo T
    Nat Rev Clin Oncol; 2016 Apr; 13(4):205-6. PubMed ID: 26902963
    [No Abstract]   [Full Text] [Related]  

  • 13. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
    Zhen DB; Coveler A; Zanon S; Reni M; Chiorean EG
    Semin Oncol; 2018 Jun; 45(3):107-115. PubMed ID: 30391013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutics: Disrupting a survival signal.
    McCarthy N
    Nat Rev Cancer; 2013 Sep; 13(9):608-9. PubMed ID: 23903094
    [No Abstract]   [Full Text] [Related]  

  • 15. Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?
    Salvia R; Malleo G; Maggino L; Milella M; Bassi C
    Updates Surg; 2020 Jun; 72(2):321-324. PubMed ID: 32445032
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
    Tinchon C; Hubmann E; Pichler A; Keil F; Pichler M; Rabl H; Uggowitzer M; Jilek K; Leitner G; Bauernhofer T
    Acta Oncol; 2013 Aug; 52(6):1231-3. PubMed ID: 23445338
    [No Abstract]   [Full Text] [Related]  

  • 17. A gut response: Modulating chemotherapy efficacy with microbial metabolites.
    Bauer KC; Greten TF
    Immunity; 2023 Apr; 56(4):750-752. PubMed ID: 37044066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unresectable locally advanced pancreatic cancer: treatment with neoadjuvant leucovorin, fluorouracil, irinotecan, and oxaliplatin and assessment of surgical resectability.
    Mondo EL; Noel MS; Katz AW; Schoeniger LO; Hezel AF
    J Clin Oncol; 2013 Jan; 31(3):e37-9. PubMed ID: 23233707
    [No Abstract]   [Full Text] [Related]  

  • 19. Pancreatic ductal adenocarcinoma: metastatic disease.
    Muñoz Martín AJ; Adeva J; Martínez-Galán J; Reina JJ; Hidalgo M
    Clin Transl Oncol; 2017 Dec; 19(12):1423-1429. PubMed ID: 28623515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets.
    Sclafani F; Iyer R; Cunningham D; Starling N
    Crit Rev Oncol Hematol; 2015 Sep; 95(3):318-36. PubMed ID: 25921418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.